Brigitte Van Eyll

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

José Baselga, J. G. M. Segalla, Henri Roché et al. · Journal of Clinical Oncology · 2012 · 160 citations · Full text

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

Paulo M. Hoff, Andreas Hochhaus, Bernhard C. Pestalozzi et al. · Journal of Clinical Oncology · 2012 · 152 citations · Full text

Signal transduction of the GLP‐1‐receptor cloned from a human insulinoma

Brigitte Van Eyll, Brigitte Lankat–Buttgereit, Hans P. Bode et al. · FEBS Letters · 1994 · 58 citations

Regular Pancreatic Islets, Signal Transduction, Molecular Physiology +14

SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).

José Baselga, H. Roché, F. Costa et al. · Cancer Research · 2009 · 52 citations

Breast Oncology, Cancer Management, Advanced Bc +17